210 related articles for article (PubMed ID: 31135837)
1. Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019.
Dusetzina SB; Huskamp HA; Keating NL
JAMA; 2019 May; 321(20):2025-2027. PubMed ID: 31135837
[TBL] [Abstract][Full Text] [Related]
2. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
[TBL] [Abstract][Full Text] [Related]
3. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
Sheingold S; Nguyen NX
Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Medicare Part D on Prescription Drug Spending and Health Care Use: 6 Years of Follow-up, 2007-2012.
Park T; Jung J
J Manag Care Spec Pharm; 2017 Jan; 23(1):5-12. PubMed ID: 28025927
[TBL] [Abstract][Full Text] [Related]
5. Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy.
Dusetzina SB; Keating NL
J Clin Oncol; 2016 Feb; 34(4):375-80. PubMed ID: 26644524
[TBL] [Abstract][Full Text] [Related]
6. Prescription Drugs-List Price, Net Price, and the Rebate Caught in the Middle.
Dusetzina SB; Bach PB
JAMA; 2019 Apr; 321(16):1563-1564. PubMed ID: 30840047
[No Abstract] [Full Text] [Related]
7. Medicare part D after 2 years.
Joyce GF; Goldman DP; Vogt WB; Sun E; Jena AB
Am J Manag Care; 2009 Aug; 15(8):536-44. PubMed ID: 19670957
[TBL] [Abstract][Full Text] [Related]
8. Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.
Dusetzina SB; Conti RM; Yu NL; Bach PB
JAMA Intern Med; 2017 Aug; 177(8):1185-1188. PubMed ID: 28558108
[TBL] [Abstract][Full Text] [Related]
9. Broken Promises - How Medicare Part D Has Failed to Deliver Savings to Older Adults.
Dusetzina SB; Muluneh B; Keating NL; Huskamp HA
N Engl J Med; 2020 Dec; 383(24):2299-2301. PubMed ID: 33283988
[No Abstract] [Full Text] [Related]
10. The relationship between the number of available therapeutic options and government payer (medicare part D) spending on topical drug products.
Kwa MC; Tegtmeyer K; Welty LJ; Raney SG; Luke MC; Xu S; Kong B
Arch Dermatol Res; 2020 Oct; 312(8):559-565. PubMed ID: 32055932
[TBL] [Abstract][Full Text] [Related]
11. The effect of Medicare Part D on drug and medical spending.
Zhang Y; Donohue JM; Lave JR; O'Donnell G; Newhouse JP
N Engl J Med; 2009 Jul; 361(1):52-61. PubMed ID: 19571283
[TBL] [Abstract][Full Text] [Related]
12. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
Raimond VC; Feldman WB; Rome BN; Kesselheim AS
Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
[TBL] [Abstract][Full Text] [Related]
13. Growing Number Of Unsubsidized Part D Beneficiaries With Catastrophic Spending Suggests Need For An Out-Of-Pocket Cap.
Trish E; Xu J; Joyce G
Health Aff (Millwood); 2018 Jul; 37(7):1048-1056. PubMed ID: 29985706
[TBL] [Abstract][Full Text] [Related]
14. Closing the Medicare Doughnut Hole: Changes in Prescription Drug Utilization and Out-of-Pocket Spending Among Medicare Beneficiaries With Part D Coverage After the Affordable Care Act.
Bonakdar Tehrani A; Cunningham PJ
Med Care; 2017 Jan; 55(1):43-49. PubMed ID: 27547949
[TBL] [Abstract][Full Text] [Related]
15. Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit.
Rotenstein LS; Dusetzina SB; Keating NL
J Manag Care Spec Pharm; 2018 Jun; 24(6):494-502. PubMed ID: 29799324
[TBL] [Abstract][Full Text] [Related]
16. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
Blumberg DM; Prager AJ; Liebmann JM
JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
[TBL] [Abstract][Full Text] [Related]
17. Part D coverage gap reform: trends in drug use and expenditures.
Park J; Look KA
Am J Manag Care; 2020 Aug; 26(8):349-356. PubMed ID: 32835462
[TBL] [Abstract][Full Text] [Related]
18. Regional variation in Medicare Part D drug spending.
Flansbaum B
N Engl J Med; 2012 May; 366(19):1842; author reply 1842-3. PubMed ID: 22571215
[No Abstract] [Full Text] [Related]
19. Regional variation in Medicare Part D drug spending.
Mukherjee D; Mukherjee C
N Engl J Med; 2012 May; 366(19):1842; author reply 1842-3. PubMed ID: 22571214
[No Abstract] [Full Text] [Related]
20. Specialty pharmacy management will become more intense.
Collins S
Manag Care; 2010 Oct; 19(10):20-3. PubMed ID: 21049783
[No Abstract] [Full Text] [Related]
[Next] [New Search]